Amgen Inc's Corporate Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %. During the corresponding time, Amgen Inc recorded a revenue increase by 5.76 % year on year, sequentially revenue fell by -12.65 %. While revenue at the Amgen Inc 's corporate clients recorded rose by 5.5 % year on year, sequentially revenue fell by -2.35 %.
Amgen Inc's Customers have recorded an advance in their cost of revenue by 8.42 % in the 1 quarter 2026 year on year, sequentially costs of revenue were trimmed by -5.98 %, for the same period Amgen Inc recorded revenue increase by 5.76 % year on year, sequentially revenue fell by -12.65 %.
Amgen Inc's Comment on Sales, Marketing and Customers
The company markets its products globally, with the United States representing approximately 73% of product sales in 2025. Key products include Prolia, used primarily for treating osteoporosis in postmenopausal women and men at high risk of fracture in the U.S. and Europe; Repatha, a PCSK9 inhibitor launched in 2015, indicated to reduce major adverse cardiovascular events and LDL-C in adults with primary hyperlipidemia; Otezla, acquired from Bristol Myers Squibb Company in 2019, approved for treating adults with plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet’s disease, and pediatric patients with moderate-to-severe plaque psoriasis, with additional approval in Japan for palmoplantar pustulosis; and ENBREL, marketed in the U.S. and Canada since 1998, used primarily for treating rheumatoid arthritis, moderate-to-severe plaque psoriasis, and active psoriatic arthritis in adults. The company serves patient populations including postmenopausal women, men with osteoporosis, adults at increased cardiovascular risk, adults and pediatric patients with psoriasis and psoriatic arthritis, and patients with Behçet’s disease. Customers and markets referenced include Bristol Myers Squibb Company and Celgene Corporation.
Amgen Inc’s Comment on Sales, Marketing and Customers
The company markets its products globally, with the United States representing approximately 73% of product sales in 2025. Key products include Prolia, used primarily for treating osteoporosis in postmenopausal women and men at high risk of fracture in the U.S. and Europe; Repatha, a PCSK9 inhibitor launched in 2015, indicated to reduce major adverse cardiovascular events and LDL-C in adults with primary hyperlipidemia; Otezla, acquired from Bristol Myers Squibb Company in 2019, approved for treating adults with plaque psoriasis, psoriatic arthritis, oral ulcers associated with Behçet’s disease, and pediatric patients with moderate-to-severe plaque psoriasis, with additional approval in Japan for palmoplantar pustulosis; and ENBREL, marketed in the U.S. and Canada since 1998, used primarily for treating rheumatoid arthritis, moderate-to-severe plaque psoriasis, and active psoriatic arthritis in adults. The company serves patient populations including postmenopausal women, men with osteoporosis, adults at increased cardiovascular risk, adults and pediatric patients with psoriasis and psoriatic arthritis, and patients with Behçet’s disease. Customers and markets referenced include Bristol Myers Squibb Company and Celgene Corporation.
Sources:
Amgen Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Amgen Inc’s corporate clients.
For your research, we’ve provided 9 tables on Amgen Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %
5.52 % 